Sun and other scientists have designed a recombinant IL-2 immune cytokine combining tumor-localizing antibodies and super mutant IL-2 (sumIL-2), which specifically binds to tumor cells and cytotoxic T cells (CTLs), thus effectively enhancing the anti-cancer effect (79). This evidence concerns the gene IL2 and cancer.